U.S. Transportation Stock News

Hope Bancorp (HOPE) drew fresh attention after its Q1 2026 report showed year-over-year growth in revenue and net income, supported by the integration of Territorial Bancorp, higher fee income, and ongoing share repurchases. See our latest analysis for Hope Bancorp. At a share price of US$12.52, HOPE has logged a 14.03% year to date share price return and a 28.10% total shareholder return over the past year. This suggests momentum has been building as investors weigh Q1 earnings, higher net...

If you are wondering whether F&G Annuities & Life is attractively priced or just looks cheap on the surface, its recent share performance gives a few clues worth unpacking. The stock last closed at US$27.08, with a 10.1% gain over the past month but a 9.0% decline over the last year and a 9.9% decline year to date, which may leave you questioning whether sentiment or fundamentals are in the driving seat. Recent coverage of F&G Annuities & Life has focused on its position as a listed insurer...

Plains GP Holdings FY 2025 earnings recap Plains GP Holdings (PAGP) has just wrapped up FY 2025 with fourth quarter revenue of US$10.6 billion and a basic EPS loss of US$0.20, as investors weigh these headline figures against a current share price of US$23.63. Over recent quarters the company has seen revenue move between US$10.6 billion and US$12.5 billion. Basic EPS has ranged from a loss of US$0.44 in late 2024 to a small profit of US$0.04 in Q3 2025. This sets the stage for a close look...

If you are wondering whether Amdocs stock is starting to look like value or a value trap, the current share price puts that question front and center. The stock closed at US$65.14 recently, with returns of 0.7% over 7 days, a 1.9% decline over 30 days, an 18.7% decline year to date and a 27.6% decline over the last year. This naturally raises questions about how the market is reassessing both growth potential and risk. Recent coverage has focused on how Amdocs fits into broader shifts in...

Kenvue (NYSE:KVUE) is progressing toward a pending US$40b acquisition by Kimberly-Clark. Shareholders and major U.S. antitrust authorities have given their approvals. The company is pursuing its 2026 Restructuring Initiative alongside the transaction process. Kenvue, a consumer health company, is at the center of one of the larger proposed deals in its sector, with a pending US$40b acquisition by Kimberly-Clark. With shareholder and key U.S. antitrust approvals already in place, investors...

In early May 2026, General Mills promoted longtime executive Dana McNabb to Chief Operating Officer and board member, expanding her remit to all global operating segments and key functions including supply chain, innovation, and digital. This leadership shift, paired with refreshed incentives for top executives, highlights General Mills’ push to tighten execution, accelerate innovation, and reinforce long-term management continuity. We’ll now examine how McNabb’s expanded operational control...

In late April 2026, Floor & Decor Holdings, Inc. outlined fiscal 2026 earnings guidance, reported softer first‑quarter results, announced plans to open 20 new warehouse stores, and authorized a US$400 million share repurchase program without an expiration date. Taken together, these updates highlight a company balancing continued store expansion with shareholder returns, while signaling its view of long‑term demand for hard‑surface flooring in the United States. Next, we’ll examine how the...

Wondering whether HubSpot at around US$243.72 is a bargain or a value trap? This article walks through what the current share price might be implying about the stock's worth. The stock has moved 9.9% over the last 7 days and 7.1% over the last 30 days, yet the return over the last year sits at a 63.1% decline and the year to date return is a 36.2% decline. Recent coverage has focused on HubSpot's position in marketing and sales software and how investors are reassessing growth stocks with...

Wondering if Adecoagro's recent share price puts it at a bargain or already reflects its strengths? This article breaks down what the current valuation is really telling you. The stock last closed at US$13.37, with a 72.3% return year to date and a 59.0% return over the past year. This is set against shorter term pullbacks of 5.1% over 7 days and 11.0% over 30 days that may signal shifting sentiment around risk and reward. Recent news around global food supply resilience, agricultural input...

Hawaiian Electric Industries (HE) has reported fourth quarter FY 2025 revenue of US$805.8 million and basic EPS of US$0.23, rounding out a trailing twelve month EPS of US$0.71 on revenue of about US$3.1 billion. The company has seen quarterly revenue move from US$799.2 million and EPS of US$0.17 in Q4 2024 to US$805.8 million and EPS of US$0.23 in Q4 2025. Over the same period, the trailing twelve month line has shifted from revenue of US$3.2 billion and EPS of a US$10.42 loss in Q4 2024 to...

If you are wondering whether MaxLinear's recent share price move has left the stock looking expensive or still potentially interesting, the valuation story is where your attention should be. The stock last closed at US$82.37, with returns of 16.4% over 7 days, 347.4% over 30 days, 345.0% year to date and a very large 1 year gain that is more than 6x. These moves sit against a backdrop of ongoing interest in semiconductor stocks, with investors watching closely for updates on demand for...

Alamar Biosciences (NasdaqGS:ALMR) doubled its revenue in Q1 2026. The company launched two new products aimed at neurodegenerative disease research. Alamar completed an IPO in 2026 to support its next phase of growth. Alamar Biosciences operates in the life sciences tools and diagnostics space, where demand for more precise protein and biomarker measurement has been a key theme for researchers and drug developers. The new products focused on neurodegenerative disease research sit in an...

Why the upcoming TN-401 data matters for Tenaya Therapeutics stock Tenaya Therapeutics (TNYA) is drawing attention as investors look ahead to new clinical safety and efficacy data for TN-401, its gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, at the ASGCT 2026 meeting. This late breaking oral presentation, together with additional abstracts on Tenaya’s gene therapy and gene editing programs, gives you fresh information to evaluate the company’s pipeline...

Brixmor Property Group Inc. recently reported first-quarter 2026 results showing year-on-year growth in revenue to US$354.82 million and net income to US$127.75 million, while also updating full-year guidance to net income of US$355 million to US$365 million and diluted EPS of US$1.16 to US$1.19. Alongside the earnings update, the board affirmed a quarterly dividend of US$0.3075 per share and highlighted that 2026 uncollectible revenues are expected to remain contained at 75 to 100 basis...

Sarepta Therapeutics (NasdaqGS:SRPT) is progressing its small interfering RNA (siRNA) candidates SRP-1001 and SRP-1003, with early data viewed as encouraging. The company is seeking to transition AMONDYS 45 and VYONDYS from accelerated to traditional FDA approvals through recent regulatory submissions. These updates come as Sarepta refines its commercial focus beyond gene therapy Elevidys, which continues to face regulatory and commercial complexity. Sarepta Therapeutics focuses on rare...

Wendy's (NasdaqGS:WEN) has announced a major franchise agreement to open up to 1,000 restaurants in China over the next decade. The expansion is part of its "Project Fresh" turnaround plan and is intended to offset weaker U.S. same-restaurant sales. The deal marks a shift in focus toward international markets as the company looks for new long term growth drivers. Wendy's, trading at around $6.95, has seen extended share price pressure, with the stock down 14.9% year to date and 39.1% over...

If you are wondering whether Chevron at around US$182.50 is offering fair value or if you are paying up for the story, this article walks through what the numbers are actually saying about the stock. The share price has pulled back recently, with a 5.6% decline over the last 7 days and a 9.4% decline over the last 30 days, while still showing returns of 17.1% year to date and 39.2% over 1 year. Recent headlines around Chevron have focused on broad energy sector sentiment and ongoing interest...

Natera (NasdaqGS:NTRA) raised its full-year 2026 revenue and gross margin guidance after reporting record test volumes. The company cited accelerating growth in both women's health and oncology segments as key drivers. Natera also outlined plans to commercially launch its Signatera MRD test in Japan, aiming to extend its international reach. Natera enters this update with its stock at $219.82 and a 1 year return of 35.2%, and a 3 year return that is a very large multiple of its earlier...

CoStar Group (NasdaqGS:CSGP) is set to be removed from the Nasdaq-100 Index. The change affects the stock's role in one of the most followed US equity benchmarks. Index adjustments can influence passive fund holdings and trading activity in the shares. For investors watching CoStar Group, the index removal intersects with a share price that most recently closed at $34.98. The stock has recorded a 1.1% return over the past week, alongside longer term declines of 11.4% over 30 days, 46.7%...

Wondering if AMETEK at around US$234.73 is offering fair value or if you might be paying up for quality? This article breaks down what the current price could mean for you. The stock has been relatively flat over the last 7 days with a 0.3% decline, but sits on gains of 7.8% over 30 days, 12.2% year to date and 37.7% over 1 year. This naturally raises questions about how much of the story is already priced in. Recent coverage has focused on AMETEK's position in the capital goods space and...

This article examines whether Energizer Holdings, at US$18.56, could be a bargain or a value trap, and explains what the current share price might be implying. The stock has recently seen mixed returns, with an 11.1% gain over the last 30 days but declines of 5.2% over 7 days, 6.9% year to date, and 11.5% over 1 year, extending to 39.8% over 3 years and 52.2% over 5 years. Recent coverage has focused on how Energizer Holdings fits into the broader household products sector, as investors...

AdvanSix (ASIX) closed out FY 2025 with Q4 revenue of US$359.9 million and a basic EPS loss of US$0.10. The trailing twelve months show EPS of US$1.83 on revenue of about US$1.5 billion. Over recent periods, revenue has moved from US$329.1 million in Q4 2024 to US$410.0 million in Q2 2025. Quarterly EPS has ranged from a small profit of US$0.01 in Q4 2024 to a high of US$1.17 in Q2 2025, giving investors a mix of profitable quarters and losses at the year end. With net profit margin at 3.2%...

In early May 2026, Wall Street analysts projected that American Public Education’s quarterly earnings per share would rise by very large year-over-year and revenue would increase by 5.6%, supported by improved student enrollment and net course registrations at Rasmussen University and Hondros College. These forecasts, alongside American Public University System’s recent commencement celebrating more than 17,700 graduates, highlight growing operational momentum across the company’s core...

Recent performance snapshot Penumbra (PEN) has drawn investor attention after recent trading, with the stock last closing at US$324.65. Short term moves have been mixed, with a small 1 day gain alongside a slight 7 day decline. See our latest analysis for Penumbra. Looking past the latest move, Penumbra’s recent share price return has been softer, with a 90 day decline of 4.8%. However, the year to date share price return of 4.92% sits alongside a 12.44% total shareholder return over the last...